Novartis Bets $7.8 Billion on Chinese RNA Platform After a Bruising September

Novartis pays $575M upfront to Abogen for worldwide rights to mRNA-encoded T-cell engager ABO2203, with $7.2B in milestones possible.

Novartis has moved to shore up its pipeline with a licensing deal that could ultimately be worth $7.8 billion, turning to Chinese biotech Abogen Biosciences for a messenger-RNA asset designed to wipe out the B cells behind severe autoimmune disease.

The Swiss drugmaker will pay $575 million upfront for worldwide exclusive rights to ABO2203, with a further $7.2 billion in development, regulatory and commercial milestones on the table should every option be exercised and every target met. Royalties on future product sales sit on top of that headline figure. The agreement, announced yesterday, remains subject to customary closing conditions and regulatory clearances.

At the center of the pact is ABO2203, an mRNA-encoded T-cell engager that binds the surface proteins CD19 and CD3. The mechanism recruits the body's own T cells to eliminate malfunctioning B cells — the same drivers implicated in a range of serious autoimmune conditions. The same class of therapy is also being explored in oncology.

Early data point to a differentiated profile

Supporting the science is a phase 1 trial in nine patients with relapsed or refractory B-cell non-Hodgkin lymphoma, presented at the AACR cancer research congress. In the highest dose cohort, the candidate produced an objective response rate of up to 100%, with no cases of cytokine release syndrome or neurological complications. Adverse events recorded in three participants resolved as treatment continued. A separate phase 1 study is now enrolling, with 66 adults planned, focused on autoimmune indications.

For Novartis, the transaction opens a door to a platform that could complement conventional cell therapies through mRNA-based mechanisms — and it lands at a moment when the geography of drug discovery is shifting. Analysts at ING expect China to account for roughly a third of all new molecules entering global pharma pipelines in 2026, up from just 4% in 2014.

A difficult late summer leaves its mark

The deal follows a testing stretch for the company's late-stage portfolio. In September, two phase 3 programs missed their goals: the HARBOR study of del-desiran in myotonic dystrophy type 1 failed to hit its primary endpoint, vHOT, while the Lp(a)HORIZON trial of pelacarsen also came up short. The setbacks wiped almost $30 billion from Novartis's market value at one point. Management is now reviewing the full HARBOR dataset to determine how del-desiran advances from here.

Investors have kept their distance. Goldman Sachs raised its price target on the stock to CHF 113 from CHF 110 on Thursday but kept a "Sell" rating in place. The shares closed Friday at EUR 125.16, down 0.4% on the day — a retreat of 10% over the past 30 days, though still 20% above the 52-week low of EUR 104.56 and up 5.9% since the start of the year.

Whether the milestone-heavy structure pays off will hinge on how ABO2203 performs in later trials, and on how it stacks up against rival approaches to immune modulation. Novartis has flagged its third-quarter and nine-month 2026 results as the next scheduled financial update.